Supplementary Table 1. Hazard Ratios Stratified by Baseline Subject and Tumor Characteristics

Variable		Leptin (ng/mL) ≥7.9 vs. <7.9	P-value	P for Interaction	Adiponectin (ng/mL) ≥13050 vs. <13050	P-value	P for Interaction	HOMA-IR ≥3.2 vs. <3.2	P-value	P for Interaction
Age				0.50			0.52			0.14
	≥ 62.0	0.51 (0.23-1.15)	0.10		2.24 (0.93-5.37)	0.07		0.47 (0.20-1.12)	0.09	
	< 62.0	0.74 (0.34-1.59)	0.44		1.61 (0.76-3.49)	0.20		1.16 (0.54-2.49)	0.70	
Gender				0.56			0.57			0.72
	Male	0.66 (0.35-1.25)	0.20		2.08 (1.11-3.90)	**0.02**		0.72 (0.38-1.34)	0.30	
	Female	0.45 (0.14-1.43)	0.18		1.35 (0.36-5.01)	0.65		0.95 (0.27-3.26)	0.93	
Hepatitis B virus				0.13			0.96			0.26
	Positive	2.06 (0.40-10.47)	0.38		1.90 (0.34-10.57)	0.45		1.82 (0.35-9.39)	0.47	
	Negative	0.51 (0.28-0.92)	**0.02**		1.72 (0.94-3.13)	0.07		0.66 (0.36-1.19)	0.17	
Hepatitis C virus				0.20			0.65			0.43
	Positive	0.44 (0.20-0.93)	**0.03**		1.69 (0.79-3.57)	0.17		0.65 (0.31-1.35)	0.25	
	Negative	0.93 (0.38-2.30)	0.88		2.05 (0.84-4.99)	0.11		0.95 (0.39-2.32)	0.92	
Diabetes mellitus				0.65			0.85			0.17
	Positive	0.31 (0.12-0.79)	**0.01**		3.24 (1.23-8.55)	**0.01**		0.30 (0.12-0.75)	**0.01**	
	Negative	0.55 (0.25-1.22)	0.14		1.96 (0.91-4.19)	0.08		0.80 (0.37-1.73)	0.57	
Alcohol history				0.49			0.19			0.47
	Positive	0.40 (0.07-2.09)	0.27		6.58 (0.79-54.78)	0.08		0.48 (0.10-2.15)	0.33	
	Negative	0.66 (0.36-1.19)	0.66		1.59 (0.88-2.88)	0.11		0.90 (0.49-1.64)	0.74	
BMI at enrollment (Kg/m^2)				0.01			0.24			0.03
	< 25	0.14 (0.02-1.12)	0.06		2.68 (0.99-7.23)	0.05		0.27 (0.06-1.18)	0.08	
	25-30	1.32 (0.55-3.14)	0.52		1.68 (0.69-4.05)	0.24		1.22 (0.50-2.96)	0.65	
	≥ 30	0.22 (0.06-0.81)	**0.02**		1.28 (0.42-3.87)	0.66		1.25 (0.33-4.66)	0.73	
Child-Pugh class				0.01			0.95			0.85
	A	0.92 (0.43-1.94)	0.83		1.52 (0.72-3.22)	0.27		0.77 (0.36-1.66)	0.51	
	B	0.26 (0.10-0.61)	**<0.01**		1.39 (0.51-3.77)	0.51		0.67 (0.29-1.53)	0.67	
Within Milan criteria				0.29			0.70			0.86
	Positive	1.52 (0.29-7.89)	0.61		2.66 (0.51-13.79)	0.24		0.81 (0.18-3.67)	0.79	
	Negative	0.66 (0.36-1.20)	0.17		1.94 (1.07-3.52)	**0.02**		0.71 (0.39-1.30)	0.27	
BCLC stage				0.54			0.91			0.62
	0,A	0.56 (0.18-1.76)	0.32		1.81 (0.57-5.74)	0.31		0.73 (0.23-2.27)	0.58	
	B,C	0.81 (0.43-1.54)	0.53		1.74 (0.92-3.28)	0.08		0.97 (0.51-1.85)	0.94	
AFP				0.40			0.79			0.40
	≥ 47.9 ng/mL	0.84 (0.41-1.71)	0.64		1.72 (0.84-3.50)	0.13		1.08 (0.53-2.19)	0.82	
	< 47.9 ng/mL	0.53 (0.22-1.29)	0.16		1.90 (0.77-4.66)	0.16		0.66 (0.27-1.64)	0.38	

Abbreviations, BMI: Body mass index; AFP: Alpha-Fetoprotein; HOMA-IR: Homeostasis model of assessment - insulin resistance; BCLC: Barcelona Clinic Liver Cancer.
Hazard ratios are not adjusted for other covariates.